ornithylaspartate has been researched along with lactulose in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 14 (63.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Eisenburg, J | 1 |
| Dicheva, DT; Iakovenko, EI; Lebedeva, EG; Maev, IV; V'iuchnova, ES | 1 |
| Carmona Soria, I; García Montes, JM; Herrerías Gutiérrez, JM; Jiménez Sáenz, M; Quero Guillén, JC | 1 |
| Bernauer, E; Finsterer, J | 1 |
| Blei, A; Grüngreiff, K; Jalan, R; Kircheis, G; Marchesini, G; Morgan, MY; Riggio, O; Weissenborn, K | 1 |
| Abdo-Francis, JM; Hernández-Vásquez, JR; Hinojosa-Ruiz, A; Pérez-Hernández, JL | 1 |
| Mittal, VV; Sarin, SK; Sharma, BC; Sharma, P | 1 |
| Abbas, Z; Abid, S; Hamid, S; Islam, M; Jafri, W; Mumtaz, K; Shah, HA | 1 |
| Fehérvári, I; Gerlei, Z; Görög, D; Kóbori, L; Nemes, B | 1 |
| Kutepov, DE; Pasechnik, IN; Sal'nikov, PS; Vershinina, MG | 1 |
| Utzt, MJ | 1 |
| Henderson, PK; Herrera, JL | 1 |
| Sussman, NL | 1 |
| Cámara-Lemarroy, CR; Delgado-García, G; Estrada-Bellmann, I; García-Valadez, E; Monreal-Robles, R | 1 |
| Arias, N; Hadjihambi, A; Jalan, R; Sheikh, M | 1 |
| Cai, XJ; Hu, CM; Wang, L | 1 |
| Abdo-Francis, JM; Alla, SN; Camacho-Aguilera, J; Higuera-de-la-Tijera, F; Jiménez-Ponce, F; Pérez-Hernández, JL; Salas-Gordillo, F; Servín-Caamaño, AI | 1 |
| Alsahhar, JS; Rahimi, RS | 1 |
| Boutros, S; Saab, S; Winters, A; Yanny, B | 1 |
| Mahpour, NY; Pioppo-Phelan, L; Reja, M; Rustgi, VK; Tawadros, A | 1 |
9 review(s) available for ornithylaspartate and lactulose
| Article | Year |
|---|---|
[Hepatic minimal encephalopathy. The most frequently overlooked, clinically occult "metabolic syndrome" on the cirrhosis patient].
Topics: Ammonia; Arginine; Dipeptides; Hepatic Encephalopathy; Humans; Lactulose; Neuropsychological Tests; Prognosis; Psychometrics | 1996 |
The treatment of hepatic encephalopathy.
Topics: Amino Acids, Branched-Chain; Anti-Bacterial Agents; Dipeptides; Hepatic Encephalopathy; Humans; Lactulose; Sugar Alcohols; Zinc | 2007 |
[Hepatic encephalopathy and liver transplantation].
Topics: Ammonia; Anti-Infective Agents; Colon; Dipeptides; Disaccharides; End Stage Liver Disease; Evidence-Based Medicine; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Hungary; Hydrogen-Ion Concentration; Lactobacillus; Lactulose; Laxatives; Liver Cirrhosis; Liver Transplantation; Metronidazole; Neomycin; Rifamycins; Rifaximin; Severity of Illness Index; Sugar Alcohols; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2012 |
Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What?
Topics: Dipeptides; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Patient Selection; Probiotics; Rifamycins; Rifaximin; Severity of Illness Index; Sickness Impact Profile | 2015 |
Treatment of Overt Hepatic Encephalopathy.
Topics: Amino Acids, Branched-Chain; Ammonia; Arteriovenous Fistula; Dipeptides; Gastrointestinal Agents; Glycerol; Hepatic Encephalopathy; Humans; Lactulose; Liver Failure; Malnutrition; Ornithine; Phenylbutyrates; Probiotics; Rifamycins; Rifaximin | 2015 |
Hepatic encephalopathy: a critical current review.
Topics: Albumins; Ammonia; Anti-Bacterial Agents; Bile Acids and Salts; Brain; Brain Edema; Cognitive Dysfunction; Dipeptides; Energy Metabolism; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Ornithine; Portasystemic Shunt, Surgical; Prognosis; Psychometrics; Severity of Illness Index; Synaptic Transmission | 2018 |
Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
Topics: Amino Acids, Aromatic; Amino Acids, Branched-Chain; Ammonia; Dipeptides; Fecal Microbiota Transplantation; Frailty; Gastrointestinal Agents; Gastrointestinal Microbiome; Glycerol; Hepatic Encephalopathy; Humans; Hypertension, Portal; Lactulose; Liver Cirrhosis; Ornithine; Phenylbutyrates; Polyethylene Glycols; Probiotics; Rifaximin; Trace Elements; Zinc | 2019 |
Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach.
Topics: Amino Acids, Branched-Chain; Ammonia; Caregivers; Cost of Illness; Dipeptides; Embolization, Therapeutic; Gastrointestinal Agents; Hepatic Encephalopathy; Hospitalization; Humans; Lactulose; Neomycin; Patient Readmission; Rifaximin; Severity of Illness Index; Sodium Benzoate; Sorption Detoxification; Zinc | 2019 |
Pharmacologic Management of Hepatic Encephalopathy.
Topics: Acarbose; Amino Acids, Branched-Chain; Anti-Bacterial Agents; Dipeptides; Fecal Microbiota Transplantation; Flumazenil; GABA Modulators; Glycerol; Glycoside Hydrolase Inhibitors; Hepatic Encephalopathy; Humans; Lactulose; Laxatives; Phenylbutyrates; Probiotics; Rifaximin | 2020 |
4 trial(s) available for ornithylaspartate and lactulose
| Article | Year |
|---|---|
[The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].
Topics: Adult; Dipeptides; Drug Therapy, Combination; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged | 2002 |
A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
Topics: Adult; Ammonia; Dipeptides; Female; Hepatic Encephalopathy; Humans; Lactulose; Male; Middle Aged; Neuropsychological Tests; Probiotics; Psychometrics; Quality of Life; Severity of Illness Index; Treatment Outcome | 2011 |
Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
Topics: Anti-Infective Agents; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Agents; Glucose; Hepatic Encephalopathy; Humans; Infusions, Intravenous; Lactulose; Length of Stay; Liver Cirrhosis; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2011 |
Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
Topics: Acute Disease; Adult; Dipeptides; Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointestinal Agents; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Rifaximin | 2018 |
9 other study(ies) available for ornithylaspartate and lactulose
| Article | Year |
|---|---|
[Chronic liver diseases. Hepatic encephalopathy too frequently overlooked?].
Topics: Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Neomycin | 2000 |
Hepatic encephalopathy: nomenclature, pathogenesis and treatment.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bromocriptine; Dipeptides; Dopamine Agonists; Electroencephalography; Flumazenil; GABA Modulators; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Failure, Acute; Liver Transplantation; Neomycin; Nutritional Physiological Phenomena; Practice Guidelines as Topic; Prognosis; Sodium Benzoate; Terminology as Topic; Time Factors; Zinc | 2003 |
[Cirrhotic liver gives up in breaking up of ammonia. Poison for the brain].
Topics: Ammonia; Clinical Trials as Topic; Dipeptides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Quality of Life; Self-Help Groups | 2004 |
Recovery from parkinson syndrome and prolonged visually evoked potentials in hepatic encephalopathy.
Topics: Anti-Bacterial Agents; Antiparkinson Agents; Benzothiazoles; Brain; Chronic Disease; Dipeptides; Evoked Potentials, Visual; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Paromomycin; Pramipexole; Recovery of Function; Thiazoles; Treatment Outcome; Vision Disorders | 2005 |
[Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy].
Topics: Adult; Aged; Dipeptides; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Length of Stay; Male; Middle Aged; Retrospective Studies | 2010 |
[Comparative effectiveness of different treatment methods of liver failure].
Topics: Comparative Effectiveness Research; Dipeptides; Extracorporeal Circulation; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Monitoring, Physiologic; Plasma Exchange; Sorption Detoxification; Treatment Outcome | 2014 |
[In Process Citation].
Topics: Ammonia; Clinical Trials as Topic; Dipeptides; Early Diagnosis; Early Medical Intervention; Evidence-Based Medicine; Hepatic Encephalopathy; Humans; Lactulose; Prognosis; Rifamycins; Rifaximin | 2015 |
Anti-ammonia treatment-responsive myoclonus as initial presentation of acquired hepatocerebral degeneration.
Topics: Ammonia; Dipeptides; Female; Hepatolenticular Degeneration; Humans; Lactulose; Middle Aged; Myoclonus | 2018 |
Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials.
Topics: Acetylcarnitine; Adult; Ammonia; Dipeptides; Female; Hepatic Encephalopathy; Humans; Lactulose; Male; Middle Aged; Network Meta-Analysis; Neuroprotective Agents; Probiotics; Randomized Controlled Trials as Topic; Rifaximin; Serum Albumin; Treatment Outcome | 2018 |